Bruno Crestani

Platelet GPVI drives fibrotic lung remodeling

Platelets are a major reservoir of bioactive mediators, including growth factors such as transforming growth factor β1 (TGF-β1), that regulate vascular repair and tissue remodeling. Beyond these classical functions, platelets also participate in inflammatory hemostasis through ac...

Antifibrotic therapy in patients with pleuroparenchymal fibroelastosis: a multicentric observational study

Pleuroparenchymal fibroelastosis (PPFE) is a rare interstitial lung disease characterized by upper-lobe predominant pleural and subpleural fibrosis and associated with poor prognosis. No evidence-based medical therapy is currently established, and lung transplantation remains the...

Timing of antifibrotic therapy and prognosis in idiopathic pulmonary fibrosis: real-world evidence from the French Colibri-ILD SNDS database

According to the French 2022 National guideline, antifibrotic therapy should be initiated as soon as a diagnosis of idiopathic pulmonary fibrosis (IPF) is made, taking into account the individual assessment of the expected benefit and risks of treatment. However, in practice, tre...